Please select the desired project time frame:
- July 2026
- January 2026
- July 2025
- January 2025
- July 2024
- January 2024
- July 2023
- January 2023
- July 2022
- January 2022
- July 2021
- January 2021
- July 2020
- January 2020
- July 2019
- January 2019
- July 2018
- January 2018
- July 2017
- January 2017
- July 2016
- January 2016
- July 2015
- January 2015
- July 2014
- January 2014
- July 2013
- January 2013
- July 2012
- January 2012
- July 2011
- January 2011
- July 2010
- January 2010
- July 2009
- January 2009
- July 2008
- January 2008
- July 2007
- January 2007
- July 2006
- January 2006
- July 2005
- January 2005
- July 2004
- January 2004
- July 2003
- January 2003
- July 2002
- January 2002
- July 2001
- January 2001
Start of funding 01.01.2009
Analysis of HDACi-mediated apoptotic and angiostatic pathways in solid human tumors
PD Dr. med. Matthias Ocker
Friedrich-Alexander-University of Erlangen-Nuremberg
Medizinische Klinik I
Dr. Richard S. Finn
University of California, Los Angeles (UCLA)
Jonsson Comprehensive Cancer Center
Pharmacologic inhibition of protein and histone deacetylases is a novel therapeutic approach in oncology. In addition to a direct influence on transcriptional activity by modifying histone proteins and nuclear transcription factors, HDACi can influence a variety of other cellular processes that regulate tumor cell survival. These processes are not fully understood or characterized yet. In this project, novel cellular processes will be investigated that are associated with cell death (apoptosis) and tumor related neovascularisation (angiogenesis). The detailed knowledge of these pathways (e.g. the unfolded protein response, endoplasmic reticulum stress or miRNA pathways) is crucial to the further clinical development of this new class of compounds in human tumor therapy.